Lung cancer in never-smokers accounts for an estimated 10–15% of UK cases, a proportion that has risen over the past decade (Gousis et al, JTO 2023, Guy’s Cancer Centre cohort, n=6,861). The patient is often younger than the cohort the NHS screening programme is built for, frequently a never-smoker or light ex-smoker, and the disease is more likely to carry an actionable driver mutation — EGFR, ALK, ROS1, RET, KRAS G12C, HER2 or others. The diagnostic pathway, the surgical decisions, and the systemic therapy options are different. For resectable stage IB–IIIA EGFR-positive disease, the current UK pathway is complete resection followed by adjuvant osimertinib for 3 years (ADAURA; NICE TA1043). Mr Lawrence Okiror is a Consultant Thoracic and Robotic Surgeon at Guy’s and St Thomas’ NHS Foundation Trust, with private practice at London Bridge Hospital and The Lister Hospital Chelsea. Private appointments typically within 2–3 working days. Self-referrals welcome. GMC 6150382.
Last reviewed: May 2026 · Mr Lawrence Okiror FRCS(CTh) FRCSEd(CTh) · GMC 6150382
Lung cancer in never-smokers is now an estimated 10–15% of UK cases and the country’s 8th most common cancer in its own right.
ADAURA 5-year overall survival 88% vs 78% with adjuvant osimertinib for resected stage IB–IIIA EGFR+ disease (Tsuboi NEJM 2023).
Current UK pathway for resectable stage IB–IIIA EGFR+: complete resection, then adjuvant chemotherapy where indicated, then osimertinib for 3 years (NICE TA1043).
The NHS Lung Cancer Screening Programme is built around a particular patient. Aged 55 to 74. Current or former smoker. Risk-stratified for early peripheral adenocarcinoma. The programme is working — over 10,000 cancers detected since 2019, more than three-quarters at stage 1 or 2 — and it is shifting the UK’s late-stage problem in the population it was designed to serve.
It is, by design, not configured to find the patient who appears in this clinic increasingly often: a never-smoker or light ex-smoker, sometimes under 50, often female, presenting either with an incidental lung finding on a CT performed for an unrelated reason — or with a brain metastasis, a pleural effusion, or persistent symptoms that have been attributed to something else for months.
An estimated 10–15% of UK lung cancers occur in never-smokers, a proportion that has risen over the past decade. The Guy’s Cancer Centre demographic and smoking-history series (Gousis et al, JTO 2023, n=6,861 referrals between 2010 and 2021) documents the institutional trend in South-East London directly. Lung cancer in never-smokers (LCINS) is now the UK’s 8th most common cancer in its own right and is recognised as a molecularly distinct disease — not the same disease as smoking-related lung cancer with the smoking removed.
Patient advocacy is shaping the public conversation. ALK Positive UK reports that 73% of its UK community have never smoked and half are under 50 at diagnosis; EGFR Positive UK provides patient support and advice for the EGFR-mutated population. Both groups are credible patient-facing references and are increasingly cited in mainstream coverage.
A risk-stratified screening programme delivers benefit by concentrating CT scans on the population most likely to have the disease. The never-smoker, the light ex-smoker, the patient under 50 — these are by definition not the population a risk-stratified programme is built for, and changing that would mean a different programme with different cost-effectiveness math. The lever in this group is not population screening. It is GP and physician awareness, faster symptomatic pathways, and a diagnostic strategy that yields enough tissue for full molecular testing on first pass.
No single classical syndrome. The four routes below cover the great majority of presentations in this population — and they share one feature: the diagnosis is rarely the first thing considered.
A CT performed for something else — trauma, back pain, an abdominal indication that captures the lung bases — reports a peripheral nodule. The patient is well, has no respiratory symptoms, has never smoked. The temptation to attribute and reassure is real and is often what happens. The British Thoracic Society nodule pathway is followed on imaging features alone; smoking status does not change the algorithm.
Particularly in EGFR-positive and ALK-positive disease, where CNS tropism is well documented, the first contact with secondary care can be the neurology, neurosurgical or oncology team after a seizure, focal neurological deficit, or persistent headache. The brain MRI shows a metastasis; the staging CT chest shows the primary. The systemic therapy decision is made before surgery is considered.
An effusion in a never-smoker is often investigated for infection, cardiac cause, or autoimmune disease before malignancy is considered. By the time pleural fluid cytology or a pleural biopsy returns the diagnosis, the disease is M1a or higher by definition. The surgical role here is usually diagnostic (VATS pleural biopsy, talc pleurodesis or indwelling pleural catheter), not curative resection.
A cough that has not resolved at 6 to 8 weeks, unexplained breathlessness, an episode of haemoptysis attributed to a recent infection. The chest X-ray may be normal or only subtly abnormal. The lesson from large cohorts is that this group experiences the longest diagnostic delay because the threshold for chest imaging in a never-smoker is higher across all stages of the pathway. A chest X-ray is not a sensitive test for an early peripheral cancer.
The under-50 cohort is particularly affected by delay
In a UK real-world cohort of under-50 NSCLC (Hughes et al, Cancers 2022 — the same South-East London institutional group as Gousis), 67% presented with metastatic disease and only 31% had treatment with curative intent. Median overall survival in metastatic NSCLC was 9.0 months overall — but 28.7 months in those with a targeted therapy option, compared with 6.6 months in those without. The implication is direct: rapid-turnaround comprehensive molecular profiling at first diagnosis is the difference between trajectories.
In the smoking population, a small bronchoscopic core that reports ‘NSCLC, not otherwise specified’ is often adequate to begin treatment planning. In the never-smoker population, it is not. The probability of an actionable driver mutation in this group is high enough that a biopsy strategy must yield tissue sufficient for a full next-generation sequencing panel — EGFR, ALK, ROS1, RET, BRAF, KRAS, HER2, MET, NTRK and others — on the first attempt.
A bronchoscopic core that returns ‘NSCLC, NOS’ in this population is a missed driver mutation, a repeat biopsy procedure, and three lost weeks. Three weeks of decision paralysis matters when the patient is 42 years old and has a 25 mm peripheral nodule.
The practical implications are operational rather than technical. Navigational bronchoscopy with cryobiopsy — either the Intuitive ION robotic platform or radial-EBUS — yields larger tissue cores than conventional flexible bronchoscopy and is the preferred first-pass modality for peripheral nodules where biopsy is required. When bronchoscopic access is unfavourable, surgical wedge biopsy (VATS or robotic) becomes the next step and frequently the simplest one. The decision is made on imaging and feasibility, not on a hierarchy.
For the technical detail on each modality, see the combined lung biopsy and robotic surgery pathway and the ION navigational bronchoscopy pages.
UK NHS Genomic Medicine Service molecular results return in approximately 10–14 days. During that window, surgical workup continues in parallel — staging CT, PET-CT, brain imaging, pulmonary function testing, cardiopulmonary exercise testing where indicated, smoking cessation support where relevant, and pre-habilitation. The patient is not paused; the pathway is run concurrently with the molecular wait.
Comprehensive molecular profiling on first diagnostic tissue. Targeted single-gene tests are not adequate in this population.
The NHS Genomic Medicine Service (GMS) provides next-generation sequencing for all newly diagnosed non-squamous NSCLC, including the actionable drivers below. Turnaround is typically 10 to 14 days from sample receipt at the genomic laboratory hub. In the never-smoker and under-50 population, the panel below should be considered the minimum standard at first diagnosis — not added later when chemotherapy stops working.
EGFR and ALK have approved adjuvant therapies after complete resection. Surgical decisions are made knowing the patient will receive 2 to 3 years of post-operative targeted therapy — this affects the conversation about the value of complete oncological resection and lymph node dissection.
ROS1, RET, KRAS G12C, HER2, NTRK, MET, BRAF currently have no adjuvant TKI standard in resected disease. Surgical resection plus standard adjuvant chemotherapy where stage indicates is the pathway, and the targeted therapy option is held in reserve for any future recurrence.
A clean molecular result early avoids the situation where a recurrence two years later requires a fresh biopsy of a difficult site, simply because the original tissue was not adequately profiled.
The decision tree below is what an MDT in 2026 should be using. Each pillar addresses a specific stage and biomarker combination; together they define which patient goes where.
Pillar 1 · Adjuvant for Resected EGFR+
Tsuboi et al, NEJM 2023;389:137–47 · Stage IB–IIIA EGFR+ · Osimertinib 3 yr vs placebo (chemo permitted)
682 patients with completely resected EGFR-mutated NSCLC randomised to osimertinib 80 mg daily for 3 years versus placebo. Adjuvant chemotherapy was permitted but not mandated — given to 76% of stage II/IIIA and 26% of stage IB. 5-year overall survival 88% (osimertinib) vs 78% (placebo); HR for death 0.49. Disease-free survival HR 0.27. Funded in the UK via the Cancer Drugs Fund managed access agreement (NICE TA1043).
UK practice implication: upfront complete resection, adjuvant chemotherapy where indicated, then osimertinib for 3 years. The default pathway in 2026.
Pillar 2 · Adjuvant for Resected ALK+
Wu et al, NEJM 2024;390:1265–76 · Stage IB(≥4 cm)–IIIA ALK+ · Alectinib 2 yr vs platinum chemo
257 patients with completely resected ALK-positive NSCLC randomised to alectinib 600 mg twice daily for 2 years versus four cycles of platinum-based chemotherapy. Stage II–IIIA disease-free survival 88.3% vs 53.3% at 3 years; HR 0.24 — a 76% reduction in recurrence or death. 4-year overall survival 98.4% in updated follow-up.
UK practice implication: alectinib replaces chemotherapy in this setting — not added to it. Different design from ADAURA. Surgery first, then 2 years of alectinib.
Pillar 3 · Neoadjuvant for Resectable EGFR+
He et al, JCO 2025; Chaft et al, ASCO 2025 LBA8001 · Stage II–IIIB N2 EGFR+ · Three-arm randomised
358 patients randomised 1:1:1 to neoadjuvant osimertinib plus chemotherapy, neoadjuvant osimertinib monotherapy, or chemotherapy plus placebo. Major pathological response (the primary endpoint): 26% (osi + chemo), 25% (osi mono), 2% (chemo + placebo). Pathological complete response 4%, 9%, 0%.
UK practice implication: directionally significant, not yet UK standard. EFS and OS data have not matured. Likely to influence the next iteration of NICE guidance; current default remains upfront surgery.
Pillar 4 · Unresectable Stage III EGFR+
Lu et al, NEJM 2024;391:585–97 · Unresectable stage III EGFR+ · Osimertinib post-CRT vs placebo
216 patients with unresectable stage III EGFR-mutated NSCLC, not progressed during or after definitive chemoradiotherapy, randomised 2:1 to osimertinib or placebo. Median PFS 38.9 months (osimertinib) vs 7.3 months (placebo); HR 0.16 — an 84% reduction in disease progression or death. New standard of care in this setting.
UK practice implication: the surgical role in this group is diagnostic only — biopsy to confirm histology and molecular status. The treatment pathway is chemoradiation followed by osimertinib consolidation.
The decision tree in one paragraph
Resectable stage IB–IIIA EGFR+ → surgery first, adjuvant chemotherapy where indicated, then 3 years of osimertinib (ADAURA). Resectable stage IB(≥4 cm)–IIIA ALK+ → surgery first, then 2 years of alectinib (ALINA). Resectable stage II–IIIB N2 EGFR+ where the MDT is considering neoadjuvant approach → NeoADAURA-directed neoadjuvant osimertinib is now an evidence-supported option, with the standard-of-care label still pending mature EFS data. Unresectable stage III EGFR+ → chemoradiation followed by osimertinib (LAURA); surgical role is diagnostic only.
A reasonable misreading of ADAURA is that adjuvant osimertinib makes the quality of surgery less important — the targeted therapy will mop up residual disease. The trial design does not support that reading. ADAURA randomised patients after complete oncological resection. Patients with R1 or R2 resections were excluded. Both arms received the same surgery; the variable tested was osimertinib versus placebo. The 88% 5-year overall survival figure is the result of complete resection plus osimertinib, not osimertinib in isolation.
The surgical principles that apply remain the same as for the smoking-population EGFR-negative patient: complete R0 resection, systematic mediastinal lymph node dissection or sampling, anatomic resection (lobectomy or where appropriate segmentectomy) rather than wedge, minimally invasive approach (VATS or robotic) where the tumour anatomy permits, and operative survival rate maintained through high-volume programme delivery. The variable that this population introduces is the post-operative pathway, not the operation.
Two surgical-decision questions arise more frequently in the never-smoker / EGFR+ cohort than in the smoker cohort:
In small (≤2 cm) peripheral early-stage NSCLC, JCOG0802 and CALGB 140503 establish anatomic segmentectomy as non-inferior to lobectomy in selected patients. In never-smokers with long expected survival, the lung-sparing argument is amplified. The choice is made on tumour position, lobar architecture, and lymph node assessment — not on smoking status alone, but in this group the bias toward parenchymal preservation is real.
The robotic platform offers superior wristed dexterity for difficult hilar dissections and complex segmentectomies. Where the surgical team is robotic-fluent and the case is technically demanding, the robotic approach is often the more conservative choice. At Guy’s and St Thomas’ the robotic share of segmentectomies was 88.9% in 2024–25 (192 of 216 cases; SCTS national audit). At London Bridge Hospital both approaches are available.
For technical detail on the operations themselves, see the segmentectomy page, the lung cancer surgery 2026 flagship, and the peripheral nodule pathway page.
ALK-positive non-small cell lung cancer accounts for around 5% of NSCLC overall, with substantial enrichment in the never-smoker and under-50 cohorts. Patients are more likely to be female, of East Asian ancestry, and to develop central nervous system metastases. ALK Positive UK reports that 73% of its UK community have never smoked and half are under 50 at diagnosis.
The ALINA trial (Wu et al, NEJM 2024) established adjuvant alectinib in resected stage IB(≥4 cm), II, or IIIA ALK-positive NSCLC. Critically, the trial design tested alectinib against platinum-based chemotherapy — not in addition to it. The 3-year disease-free survival of 88.3% in the alectinib arm compared with 53.3% in the chemotherapy arm represents a 76% reduction in recurrence or death (HR 0.24). The 4-year overall survival update is 98.4% in the alectinib arm.
The practical UK MDT consequence is that the post-operative conversation for the ALK+ patient is fundamentally different from the EGFR+ patient. Where ADAURA stacks osimertinib on top of standard chemotherapy, ALINA substitutes alectinib for it. The patient does not receive adjuvant cisplatin-based chemotherapy and its associated toxicity profile in the ALINA pathway.
Stage III is the heterogeneous middle ground. Some stage III disease is resectable (single-station N2, fit patient, technically resectable primary). Some is not (multi-station or bulky N2, poor lung function, anatomically unresectable primary). The resectability decision is made by the MDT and is independent of EGFR status — but the post-decision pathway is determined by it.
Resectable stage III EGFR+: upfront surgery, adjuvant chemotherapy where indicated, adjuvant osimertinib for 3 years (the ADAURA pathway). NeoADAURA-directed neoadjuvant osimertinib is now an evidence-supported option for the MDT to consider, particularly in the bulkier resectable stage IIIA where pathological downstaging is desirable.
Unresectable stage III EGFR+: definitive concurrent chemoradiotherapy followed by osimertinib consolidation (the LAURA pathway). Median PFS in the LAURA trial was 38.9 months on osimertinib compared with 7.3 months on placebo — an 84% reduction in disease progression. The surgical role here is the original diagnostic biopsy that confirmed histology, EGFR status, and the unresectability decision.
For comprehensive coverage of the locally-advanced cancer pathway, see the lung cancer surgery 2026 flagship guide.
A subset of EGFR-positive patients on osimertinib for advanced disease will develop limited progression at one or two sites while the rest of the disease remains controlled. The pattern — sometimes called oligoprogression — is becoming more common as the duration of disease control on third-generation EGFR-TKIs lengthens. In selected patients, surgical resection of the progressing site (or radiotherapy where surgery is unfavourable) while continuing osimertinib can extend the duration of treatment benefit substantially.
The same principle applies to a smaller subset of patients with oligometastatic disease at presentation — a primary lung tumour with one or two synchronous metastatic sites, EGFR-positive on biopsy, considered for systemic therapy with possible later local consolidation of the residual primary and metastatic sites.
The decision is MDT-led and individualised. The surgical principles are unchanged from non-targeted-therapy oligometastatic resection: a clean operation that does not delay the resumption of systemic therapy, a robust tissue sample for re-profiling (where the resected metastasis may have developed resistance mechanisms different from the primary), and realistic conversations with the patient about the intent of the operation. The role is real and growing; see the pulmonary metastasectomy and cancer spread to the lungs pages for the broader metastasectomy framework.
Lung cancer in never-smokers is managed through the same multidisciplinary structure as smoking-related lung cancer. The thoracic oncology MDT at Guy’s and St Thomas’ meets weekly, brings together surgery, medical oncology, clinical oncology, radiology, interventional radiology, respiratory medicine, palliative care, and specialist nursing, and discusses every new diagnosis before treatment is initiated. Molecular results from the NHS Genomic Medicine Service hub return within approximately 10 to 14 days and inform the MDT decision.
Patient-led advocacy organisations are an increasingly important part of the pathway for this population. Both groups below are clinically-advised, well-curated, and worth recommending to patients and families directly.
UK patient charity providing information, peer support, and clinical advice for people with EGFR-mutated lung cancer. Clinically advised, with expert input from UK thoracic oncologists.
UK patient charity for ALK-positive lung cancer. Publishes UK community data showing 73% never-smoker and 50% under-50 distribution. Active in policy and awareness work.
Patients with a known or suspected lung cancer that may not fit the standard smoking-related profile — never-smokers, light ex-smokers, the under-50 cohort with an unexplained finding — are seen privately at London Bridge Hospital and The Lister Hospital Chelsea, typically within 2 to 3 working days. Mr Okiror reviews all prior imaging and laboratory results personally before the consultation.
The structure of a typical first consultation in this population:
A brief referral letter with the current CT chest, any prior imaging for comparison, and a summary of presenting symptoms is sufficient. Self-referrals welcome.
Contact Jo Mitchelson, PA: 020 7952 2882 — pa@lungsurgeon.co.uk
Common questions from patients with a known or suspected diagnosis, from families seeking a second opinion, and from referring clinicians weighing the right next step.
Book a Consultation →Or call Jo Mitchelson, PA:
020 7952 2882
Private appointments at London Bridge Hospital and The Lister Hospital Chelsea within 2–3 working days. Mr Okiror reviews investigations personally and advises honestly on the appropriate next step in the pathway. Self-referrals welcome.
Jo Mitchelson, PA · 020 7952 2882 · pa@lungsurgeon.co.uk
St Thomas’ Hospital #1 UK · Guy’s Hospital #2 UK · London Bridge Hospital #10 UK · Newsweek World’s Best Hospitals 2026
Key References
Flagship clinical guide — stages, segmentectomy vs lobectomy, robotic surgery, adjuvant therapy
Shadow on Lung or CT ScanPatient-facing orientation page on the incidental lung nodule pathway
Combined Biopsy & Robotic SurgeryNavigational bronchoscopy and robotic resection in a single anaesthetic — the first-pass tissue strategy